OverviewSuggest Edit

PolarityTE, Inc. is a regenerative medicine company positioned to be the first to successfully regenerate human skin. If clinically successful, the PolarityTE platform will be able to provide medical professionals with a truly new paradigm in wound healing and reconstructive surgery by utilizing a patient's own tissue substrates for the regeneration of skin, bone, muscle, cartilage, fat, blood vessels and nerves. It is because PolarityTE uses a natural and biologically sound platform technology, which is readily adaptable to a wide spectrum of organ and tissue systems, that the company and its world-renowned clinical advisory board, are poised to drastically change the field and future of translational regenerative medicine.

TypePublic
Founded1986
HQSalt Lake City, UT, US
Websitepolarityte.com
Employee Ratings3.5

Latest Updates

Employees (est.) (Dec 2018)156(+27%)
Job Openings4
Revenue (FY, 2020)$10.1 M(+80%)
Share Price (Dec 2021)$0.6(+31%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at PolarityTE

Nikolai Sopko

Nikolai Sopko

Chief Scientific Officer & VP R&D
Peter Cohen

Peter Cohen

Chairman of the Board
Cameron Hoyler

Cameron Hoyler

General Counsel & EVP Corporate Development & Strategy
Jessica Shen

Jessica Shen

Director
Willie Bogan

Willie Bogan

Director
Jacob Patterson

Jacob Patterson

Interim Chief Financial Officer
Show more

PolarityTE Office Locations

PolarityTE has an office in Salt Lake City
Salt Lake City, UT, US (HQ)
123 N Wright Brothers Dr
Salt Lake City, UT, US
1960 S 4250 W
Show all (2)

PolarityTE Financials and Metrics

PolarityTE Revenue

PolarityTE's revenue was reported to be $10.13 m in FY, 2020
USD

Revenue (Q1, 2021)

4.7m

Gross profit (Q1, 2021)

2.5m

Gross profit margin (Q1, 2021), %

54%

Net income (Q1, 2021)

(17.4m)

EBIT (Q1, 2021)

(8.2m)

Market capitalization (31-Dec-2021)

36.7m

Closing stock price (31-Dec-2021)

0.6

Cash (31-Mar-2021)

37.2m

EV

3.1m
PolarityTE's current market capitalization is $36.7 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

125.3m132.3m47.3m34.4m6.7m1.5m673.0k5.7m10.1m

Revenue growth, %

(27%)(81%)(77%)

Cost of goods sold

79.8m88.8m35.1m28.7m3.4m286.0k381.0k2.5m4.4m

Gross profit

45.5m43.5m12.2m5.7m3.3m1.3m292.0k3.2m5.7m
USDQ3, 2011

Financial Leverage

1.5 x
Show all financial metrics

PolarityTE Cybersecurity Score

Cybersecurity ratingPremium dataset

A

94/100

SecurityScorecard logo

PolarityTE Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

PolarityTE Online and Social Media Presence

Embed Graph

PolarityTE News and Updates

POLARITYTE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against PolarityTE, Inc. and Encourages Investors to Contact the Firm

NEW YORK, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against PolarityTE, Inc. (“PolarityTE” or the “Company”) (NASDAQ: PTE) in the United States District Court …

POLARITYTE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against PolarityTE, Inc. and Encourages Investors to Contact the Firm

NEW YORK, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against PolarityTE, Inc. (“PolarityTE” or the “Company”) (NASDAQ: PTE) in the United States District Court …

ROSEN, A LEADING LAW FIRM, Encourages PolarityTE, Inc. Investors to Secure Counsel Before Important November 23 Deadline in Securities Class Action – PTE

NEW YORK, Nov. 02, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of PolarityTE, Inc. (NASDAQ: PTE) between April 30, 2020 and August 23, 2021, inclusive (the “Class Period”), of the important November 23, 2021 lead plaintiff d…

ROSEN, A LEADING LAW FIRM, Encourages PolarityTE, Inc. Investors With Losses to Secure Counsel Before Important November 23 Deadline in Securities Class Action – PTE

WHY: NEW YORK, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of PolarityTE, Inc. (NASDAQ: PTE) between April 30, 2020 and August 23, 2021, inclusive (the “Class Period”), of the important November 23, 2021 lead plaintiff d…

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against PolarityTE, Hyzon Motors, Nano-X, and Eargo and Encourages Investors to Contact the Firm

NEW YORK, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of PolarityTE, Inc. (NASDAQ: PTE), Hyzon Motors, Inc. (NASDAQ: HYZN), Nano-X Imaging …
Show more

PolarityTE Blogs

PolarityTE Announces U.S. FDA Approval of IND for Pivotal Phase 3 Study of SkinTE® to Support Chronic Cutaneous Ulcer Indication

SALT LAKE CITY, Jan. 18, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, today announced that the U.S. Food and Drug Administration (FDA) has approved its investigational new drug (IND) application for the ev…

PolarityTE Announces Submission of Complete Response to FDA's Clinical Hold Correspondence for SkinTE® Investigational New Drug Application

SALT LAKE CITY, Dec. 20, 2021 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing regenerative tissue products and biomaterials, today announced that it has submitted its complete response to the U.S. Food and Drug Administration's (FDA) clinical hold correspondence r…

PolarityTE Reports Third Quarter Financial Results and Provides Business Update

PolarityTE to host conference call and webcast today, November 10, 2021, at 8:30 a.m. ET SALT LAKE CITY, Nov. 10, 2021 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing regenerative tissue products and biomaterials, today provided a business update and reported finan…

PolarityTE to Report Third Quarter Financial Results on November 10, 2021

SALT LAKE CITY, Oct. 28, 2021 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) today announced that it will report results for the quarter ended September 30, 2021 by press release on Wednesday, November 10, 2021 at approximately 7:00 a.m. Eastern Time. …

PolarityTE to Attend H.C. Wainwright 23rd Annual Global Investment Conference and 2021 Cantor Virtual Global Healthcare Conference

SALT LAKE CITY--(BUSINESS WIRE)-- PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing regenerative tissue products and biomaterials, announced today that it will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021 and participate in a fires…

PolarityTE Appoints Richard Hague as Chief Executive Officer and Elects David Seaburg to Board of Directors and Chair of Strategic Review Committee

Ryan Mathis, MD, named Chief Medical Officer SALT LAKE CITY--(BUSINESS WIRE)-- PolarityTE, Inc. (Nasdaq: PTE) today announced the appointment of Richard Hague as Chief Executive Officer, the election of David Seaburg to the Board of Directors, and the appointment of Ryan Mathis, MD, as Chief M…
Show more

PolarityTE Frequently Asked Questions

  • When was PolarityTE founded?

    PolarityTE was founded in 1986.

  • Who are PolarityTE key executives?

    PolarityTE's key executives are Nikolai Sopko, Peter Cohen and Cameron Hoyler.

  • How many employees does PolarityTE have?

    PolarityTE has 156 employees.

  • What is PolarityTE revenue?

    Latest PolarityTE annual revenue is $10.1 m.

  • What is PolarityTE revenue per employee?

    Latest PolarityTE revenue per employee is $64.9 k.

  • Who are PolarityTE competitors?

    Competitors of PolarityTE include Fibroheal, PhosphoSolutions and Silk Technologies.

  • Where is PolarityTE headquarters?

    PolarityTE headquarters is located at 123 N Wright Brothers Dr, Salt Lake City.

  • Where are PolarityTE offices?

    PolarityTE has an office in Salt Lake City.

  • How many offices does PolarityTE have?

    PolarityTE has 2 offices.